185 related articles for article (PubMed ID: 11106671)
1. Consensus panel endorses range of adjuvant therapies for breast cancer.
McNeil C
J Natl Cancer Inst; 2000 Dec; 92(23):1870. PubMed ID: 11106671
[No Abstract] [Full Text] [Related]
2. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
3. Trial data lacking for elderly patients with breast cancer.
Nelson NJ
J Natl Cancer Inst; 2000 Dec; 92(24):1968-9. PubMed ID: 11121451
[No Abstract] [Full Text] [Related]
4. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
5. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
6. [Report on the NIH Consensus Development Conference on Adjuvant Therapy of Breast Carcinoma].
Kaufmann M; von Minckwitz G
Onkologie; 2001 Apr; 24(2):190-2. PubMed ID: 11441303
[No Abstract] [Full Text] [Related]
7. [Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
Sauer R; Martus P
Strahlenther Onkol; 1996 Sep; 172(9):516-7. PubMed ID: 8928060
[No Abstract] [Full Text] [Related]
8. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
10. The 1998 St. Gallen's Consensus Conference: an assessment.
Zujewski J; Liu ET
J Natl Cancer Inst; 1998 Nov; 90(21):1587-9. PubMed ID: 9811303
[No Abstract] [Full Text] [Related]
11. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
12. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
Wolff AC; Davidson NE
J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
[No Abstract] [Full Text] [Related]
13. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
Giannessi PG
Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
[No Abstract] [Full Text] [Related]
14. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
15. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
16. Presurgical progesterone in early breast cancer: so much for so little?
Dowsett M; Smith IE
J Clin Oncol; 2011 Jul; 29(21):2839-41. PubMed ID: 21670461
[No Abstract] [Full Text] [Related]
17. Taxane evidence inconclusive in adjuvant setting.
Randal J
J Natl Cancer Inst; 2001 Feb; 93(3):168-9. PubMed ID: 11158179
[No Abstract] [Full Text] [Related]
18. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
19. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
20. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
